"The focus of our integrated Translational Pharmaceutics programs is to provide the customer with a development platform capable of responding in real-time to emerging development data and maintain an overall timeline to proof of concept."
"We were excited to secure equity investment from Signet Healthcare Partners and have since almost doubled in size in both our capacity and talent pool."
"Insmed developed a drug-device combination that became the first approved therapy to treat patients with a refractory form of a rare and serious lung infection."
SENIOR VICE PRESIDENT OF POLICY, RESEARCH AND MEMBERSHIP, PHRMA
"Our organization advocates for public policies that encourage the research and development and manufacturing of new medicines that allow patients to lead longer, healthier, and more productive lives."
"Tele-health tactics gained momentum and our clients made their pivot, like other industries, to fully remote operations. RxS, with our technology-forward approach, was prepared for the shift."
PRESIDENT – US INFECTIOUS DISEASES & VACCINES, JANSSEN PHARMACEUTICALS
"In vaccines, we are progressing late-stage programs of break-through vaccines against diseases where vaccines are not currently available, such as RSV and multidrug resistant bacterial infections, including ExPEC and Staphylococcus aureus."
The pre-release edition of Africa Energy 2024 comprises analysis based on over 80 interviews with ministers and leading executives from IOCs, NOCs, independents, associations, investors and service providers, to provide an in-depth and holistic view of sub-Saharan Africa’s ever-evolving energy sector.